Journal article
Clinical experience with cold plasma in the treatment of locally advanced head and neck cancer
Clinical plasma medicine, v 9, pp 6-13
Mar 2018
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Cold atmospheric pressure plasma (CAP) is well known for inactivating microbial pathogens and stimulation of tissue regeneration in chronic wounds. Several authors have reported the effectiveness against cancer in different cell lines and animal models. This is the first report of patients with real clinical benefit following application of CAP, not just visible change of the tumor surface but lasting partial remission. The authors discuss the CAP treatment approach and the efficacy for inoperable head and neck cancer patients.
The trial enrolled six patients with locally advanced (pT4) squamous cell carcinoma of the oropharynx suffering from open infected ulcerations. Patients were treated with a jet plasma source (kINPen MED, neoplas tools GmbH, Greifswald, Germany) in cycles of 3 single applications (1 min/cm2 from a distance of 8 mm) within 1 week, each followed by an intermittence of 1 week.
CAP treatment resulted in a reduction in odor and pain medication requirements, in improvement in social function and a positive emotional affect. Further observance revealed partial remission in two patients for at least nine month. Incisional biopsies at remission demonstrate a moderate amount of apoptotic tumor cells and a desmoplastic reaction of the connective tissue.
The trial demonstrates the clinical relevance of CAP in cancer treatment. There are three approaches for discussion of tumor remission: (i) the role of myeloid cells, (ii) the ROS/RNS model of cellular impact and (iii) the immunogenic cell death model of cancer treatment, and there is a reflection on non-sustainable tumor response due to adapted tumor microenvironment.
Metrics
Details
- Title
- Clinical experience with cold plasma in the treatment of locally advanced head and neck cancer
- Creators
- Hans-Robert Metelmann - Greifswald University HospitalChristian Seebauer - Leibniz Institute for Plasma Science and TechnologyVandana Miller - Drexel UniversityAlexander Fridman - Drexel UniversityGeorg Bauer - University of FreiburgDavid B. Graves - University of California, BerkeleyJean-Michel Pouvesle - University of OrléansRico Rutkowski - Greifswald University HospitalMatthias Schuster - Greifswald University HospitalSander Bekeschus - Leibniz Institute for Plasma Science and TechnologyKristian Wende - Leibniz Institute for Plasma Science and TechnologyKai Masur - Leibniz Institute for Plasma Science and TechnologySybille Hasse - Leibniz Institute for Plasma Science and TechnologyTorsten Gerling - Leibniz Institute for Plasma Science and TechnologyMasaru Hori - Institute of Innovation for Future Society, Nagoya University,JapanHiromasa Tanaka - Institute of Innovation for Future Society, Nagoya University,JapanEun Ha Choi - Plasma Bioscience Research Center, Kwangwoon University, Seoul, Republic of KoreaKlaus-Dieter Weltmann - Leibniz Institute for Plasma Science and TechnologyPhiline Henriette Metelmann - Greifswald University HospitalDaniel D. Von Hoff - Translational Genomics Research InstituteThomas von Woedtke - Leibniz Institute for Plasma Science and Technology, Greifswald, Germany
- Publication Details
- Clinical plasma medicine, v 9, pp 6-13
- Publisher
- Elsevier GmbH
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology; Mechanical Engineering and Mechanics
- Web of Science ID
- WOS:000433744800002
- Scopus ID
- 2-s2.0-85043524104
- Other Identifier
- 991019168309404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Medicine, Research & Experimental